Avadel Pharmaceuticals Plc (AVDL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Avadel Pharmaceuticals Plc (AVDL)
Go deeper and ask any question about AVDL
Company Performance
Current Price
as of Sep 13, 2024$13.70
P/E Ratio
N/A
Market Cap
$1.32B
Description
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Metrics
Overview
- HQDublin, DU
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerAVDL
- Price$13.7-1.76%
Trading Information
- Market Cap$1.32B
- Float93.85%
- Average Daily Volume (1m)985,377
- Average Daily Volume (3m)1,310,771
- EPS-$1.15
Company
- Revenue$95.15M
- Rev Growth (1yr)2,674.33%
- Net Income-$13.82M
- Gross Margin93.28%
- EBITDA Margin-29.65%
- EBITDA-$12.30M
- EV$1.32B
- EV/Revenue13.85
- P/EN/A
- P/S13.84
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset